These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 25827132)

  • 1. Targeting the immune system to treat lung cancer: rationale and clinical experience.
    Guibert N; Delaunay M; Mazières J
    Ther Adv Respir Dis; 2015 Jun; 9(3):105-20. PubMed ID: 25827132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors in lung cancer: past, present and future.
    Seetharamu N; Budman DR; Sullivan KM
    Future Oncol; 2016 May; 12(9):1151-63. PubMed ID: 27019997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
    Langer CJ
    Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the immune system in the treatment of non-small-cell lung cancer.
    Rangachari D; Brahmer JR
    Curr Treat Options Oncol; 2013 Dec; 14(4):580-94. PubMed ID: 23934510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immune alterations in lung cancer - the new therapeutic approach].
    Domagała-Kulawik J; Osińska I
    Pneumonol Alergol Pol; 2014; 82(3):286-99. PubMed ID: 24793154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint therapy for non-small-cell lung cancer: an update.
    Xia B; Herbst RS
    Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for lung cancer: ongoing clinical trials.
    Declerck S; Vansteenkiste J
    Future Oncol; 2014 Jan; 10(1):91-105. PubMed ID: 24143916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.
    Howell M; Lee R; Bowyer S; Fusi A; Lorigan P
    Lung Cancer; 2015 May; 88(2):117-23. PubMed ID: 25776466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy and lung cancer: current developments and novel targeted therapies.
    Domingues D; Turner A; Silva MD; Marques DS; Mellidez JC; Wannesson L; Mountzios G; de Mello RA
    Immunotherapy; 2014; 6(11):1221-35. PubMed ID: 25496336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
    Spigel DR; Socinski MA
    J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint blocking antibodies in cancer immunotherapy.
    Kyi C; Postow MA
    FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
    Kawano M; Itonaga I; Iwasaki T; Tsumura H
    Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promising immunotherapies for esophageal cancer.
    Tanaka T; Nakamura J; Noshiro H
    Expert Opin Biol Ther; 2017 Jun; 17(6):723-733. PubMed ID: 28366014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.
    Blank CU
    Curr Opin Oncol; 2014 Mar; 26(2):204-14. PubMed ID: 24424272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of immunotherapy in the treatment of advanced non-small-cell lung cancer.
    Rijavec E; Genova C; Alama A; Barletta G; Sini C; Pronzato P; Coco S; Dal Bello MG; Savarino G; Truini A; Boccardo F; Grossi F
    Future Oncol; 2014 Jan; 10(1):79-90. PubMed ID: 24328411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.
    Hall RD; Gray JE; Chiappori AA
    Cancer Control; 2013 Jan; 20(1):22-31. PubMed ID: 23302904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human vaccines & immunotherapeutics: news.
    Riedmann EM
    Hum Vaccin Immunother; 2013 Jul; 9(7):1395-8. PubMed ID: 23863285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer].
    Wang S; Li J
    Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):682-686. PubMed ID: 27760599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.